Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.72 |
| ▸ | CSF1R | P07333 | 5/20 | 0.67 |
| ▸ | KIT | P10721 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487127 | 0.93 | BRAF (0.70) | BRAFCSF1RKITGAALCK | |
| SCHEMBL27483417 | 0.86 | KCNK3 (0.54) | BRAFCSF1RKITHTTMEN1 | |
| SCHEMBL6486638 | 0.85 | NPC1 (0.60) | BRAFKITMAPK14RAF1PDGFRA | |
| SCHEMBL19073209 | 0.82 | BRAF (0.73) | BRAFCSF1RKITGAALCK | |
| SCHEMBL6485907 | 0.82 | MAPK14 (0.77) | BRAFCSF1RMAPK14RAF1KCNK3 | |
| SCHEMBL5896949 | 0.82 | CSF1R (0.75) | BRAFCSF1RKITLCKSRC | |
| SCHEMBL6779119 | 0.81 | POLB (0.70) | BRAFCSF1RKITGAALCK | |
| SCHEMBL22065317 | 0.81 | BRAF (0.72) | BRAFCSF1RKITGAALCK | |
| SCHEMBL6482600 | 0.81 | MAPK14 (0.56) | BRAFMAPK14RAF1MEN1RAB9A | |
| SCHEMBL15127735 | 0.81 | BRAF (0.72) | BRAFCSF1RKITGAALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-6686467-B2 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 | ZENECA LIMITED (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| US-6498274-B1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED (GB) | 2002-12-24 | — | — | US | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | BRAF 1768/4885CSF1R 430/4885KIT 532/4885 |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | BRAF 3474/4885CSF1R 92/4885KIT 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.